Drug Trial Radar · NCT00077623
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
Last checked: Nov 20, 2026Latest source record: May 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
572
Actual
Start
Mar 2004
Primary completion
Sep 2005
Study completion Sep 2005
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Feb 13, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy and safety of subcutaneous (sc) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving sc epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.
Conditions
- Anemia
Interventions
epoetin alfa or betaDrug
iv 3 times weekly, as prescribed
methoxy polyethylene glycol-epoetin beta (Mircera)Drug
60, 100 or 180 micrograms sc (starting dose) every 2 weeks
methoxy polyethylene glycol-epoetin beta (Mircera)Drug
60, 100 or 180 micrograms sc (starting dose) every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change in Hemoglobin Concentration From Baseline to Evaluation PeriodsTime frame: Baseline (Week -4 to Week -1) and Evaluation period (Week 29 to Week 36)
Locations
90 sites in 21 countries. Site status is shown where the registry gives one.
Site not named
Hot Springs, Arkansas
Site not named
Los Angeles, California
Site not named
Riverside, California
Site not named
Sacramento, California
Site not named
San Jose, California
Site not named
Boston, Massachusetts
Site not named
Springfield, Massachusetts
Site not named
Detroit, Michigan
Site not named
Brooklyn Center, Minnesota
Site not named
Raleigh, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Toledo, Ohio
Site not named
Portland, Oregon
Site not named
Dallas, Texas
Site not named
Houston, Texas
Site not named
San Antonio, Texas
Site not named
Morgantown, West Virginia
Site not named
Brussels, Belgium
Site not named
Edegem, Belgium
Site not named
Ghent, Belgium
Site not named
Hasselt, Belgium
Site not named
Curitiba, Brazil
Site not named
São Paulo, Brazil
Site not named
São Paulo, Brazil
Site not named
Brno, Czechia
Site not named
Ostrava, Czechia
Site not named
Pilsen, Czechia
Site not named
Odense, Denmark
Site not named
HUS, Finland
Site not named
Tampere, Finland
Site not named
Turku, Finland
Site not named
Bayonne, France
Site not named
Boulogne, France
Site not named
Cabestany, France
Site not named
Caen, France
Site not named
Limoges, France
Site not named
Nîmes, France
Site not named
Pantin, France
Site not named
Poitiers, France
Site not named
Saint-Germain-en-Laye, France
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.